iRadimed (NASDAQ:IRMD) Releases FY 2025 Earnings Guidance

Key Points

• iRadimed has updated its FY 2025 earnings guidance, projecting earnings per share (EPS) between 1.760-1.860 and revenue of $80.0 million-$82.5 million, exceeding consensus estimates.
• The company recently announced a quarterly dividend of $0.17 per share, translating to an annual yield of 1.2%.
• Wall Street has upgraded iRadimed's stock from a "buy" to a "strong-buy" rating, reflecting increased confidence among analysts.

iRadimed (NASDAQ:IRMD - Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 1.760-1.860 for the period, compared to the consensus EPS estimate of 1.735. The company issued revenue guidance of $80.0 million-$82.5 million, compared to the consensus revenue estimate of $79.4 million. iRadimed also updated its Q3 2025 guidance to 0.450-0.490 EPS.

iRadimed Stock Performance

Shares of NASDAQ IRMD traded down $1.28 during midday trading on Tuesday, reaching $69.41. 67,035 shares of the company's stock were exchanged, compared to its average volume of 43,900. iRadimed has a 52-week low of $43.17 and a 52-week high of $71.91. The stock has a market capitalization of $882.90 million, a PE ratio of 42.85 and a beta of 0.94. The business's fifty day moving average price is $59.02 and its two-hundred day moving average price is $55.92.

iRadimed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 28th. Stockholders of record on Monday, August 18th will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Monday, August 18th. iRadimed's payout ratio is presently 41.98%.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised iRadimed from a "buy" rating to a "strong-buy" rating in a report on Tuesday, May 6th.

Hedge Funds Weigh In On iRadimed

Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new stake in shares of iRadimed in the 1st quarter worth about $369,000. Goldman Sachs Group Inc. increased its holdings in shares of iRadimed by 1.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider's stock worth $8,889,000 after acquiring an additional 1,821 shares during the period. Jones Financial Companies Lllp grew its holdings in iRadimed by 8,568.5% in the 1st quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider's stock worth $591,000 after buying an additional 11,139 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock worth $252,000 after buying an additional 234 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in iRadimed by 7.5% in the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider's stock worth $831,000 after buying an additional 1,108 shares in the last quarter. 92.34% of the stock is owned by institutional investors.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.